APAri Polachek

Ari Polachek

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ari Polachek has a total of 139 co-authors. Here are the top co-authors by number of shared publications:

  • Ori Elkayam

    Rheumatology Department, Tel Aviv Sourasky Medical Center, Tel Aviv; and Tel Aviv University Faculty of Medicine, Tel Aviv, Israel

    13 shared publications
  • Victoria Furer

    Department of Rheumatology, Tel-Aviv Sourasky Medical Center, Tel-Aviv, Israel

    11 shared publications
  • David Levartovsky

    Rheumatology Department, Tel Aviv Sourasky Medical Center, Tel Aviv; and Tel Aviv University Faculty of Medicine, Tel Aviv, Israel

    9 shared publications
  • Smadar Gertel

    Department of Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel

    8 shared publications
  • Jonathan Wollman

    Rheumatology Department, Tel Aviv Sourasky Medical Center, Tel Aviv; and Tel Aviv University Faculty of Medicine, Tel Aviv, Israel

    7 shared publications
  • Daphna Paran

    Rheumatology Department, Tel Aviv Sourasky Medical Center, Tel Aviv; and Tel Aviv University Faculty of Medicine, Tel Aviv, Israel

    6 shared publications

Latest Publications

  • Open Access

    The development and validation of a new diagnostic sonographic enthesitis score for psoriatic arthritis: Diagnostic Ultrasound Enthesitis Tool ( DUET )

    by Lihi Eder, Andre L. Ribeiro, Ricardo Acayaba de Toledo, Catherine Bakewell, Philippe Carron, Basant Elnady, Amir Haddad, Arthur Kavanaugh, Arnon Katz, Minna J. Kohler, et al.

    Objective: The Diagnostic Ultrasound Enthesitis Tool (DUET) study aimed to develop and validate a new sonographic scoring system for enthesitis to aid PsA diagnosis. Methods: We prospectively enrolled patients with early PsA, psoriasis without arthritis (PsO), and non‐inflammatory musculoskeletal symptoms as controls (CTL) from 17 centers. A standardized ultrasound assessment of 16 entheseal sites was performed and images were centrally scored by three blinded readers for inflammatory and structural entheseal lesions. Using a stepwise approach with logistic regression models stratified by age, we identified optimal lesion combinations, weightings, and entheseal sites for distinguishing PsA from CTL. Age‐specific cut‐off points were selected to maintain specificity above 70%. Performance was assessed in a validation cohort of PsA and CTL. Results: We included 213 PsA, 100 PsO, and 106 CTL in the discovery cohort. The final DUET score combined weighted inflammatory (hypoechogenicity + thickening + Doppler grade x 2) and structural (enthesophyte grade + erosion x 3) scores at three entheseal sites: Achilles, proximal patellar tendon insertion, and triceps. Age stratification (≤55 vs. >55 years) improved discriminative performance. In the discovery cohort, DUET achieved an AUC of 0.65, with specificity of 73‐74% and sensitivity of 47‐49%. In an external validation cohort (101 PsA, 69 CTL), specificity improved to 74‐100% with similar sensitivity (49‐52%). Sensitivity increased up to 63% in patients with tender entheses. Conclusion: DUET is a novel, externally validated sonographic enthesitis score that could support the diagnostic assessment of patients with early PsA, particularly in individuals with tender entheses.

  • Semen analysis of patients with psoriatic arthritis, axial spondyloarthritis and healthy controls

    by Katya Meridor, Shimi Barda, Ofir Elalouf, Victoria Furer, Sara Pel, Hila Nochomovitz, Michael Zisapel, Jonathan Wollman, Reut Tzemach, Mark Berman, et al.

    To evaluate semen quality in men with psoriatic arthritis (PsA) or axial spondyloarthritis (AxSpA) compared to healthy controls (HC) and to investigate the effect of disease activity and disease-modifying antirheumatic drugs (DMARDs) on semen parameters. Consecutive PsA (CASPAR criteria) and AxSpA patients (ASAS criteria) aged 18-50 years either untreated or undergoing treatment with conventional/biologic DMARDs for at least 3 months were prospectively recruited. HC were recruited from candidate sperm donors. All participants underwent clinical assessments, including disease activity scoring. Semen samples collected on the same day as the clinical evaluation were analysed according to WHO 2010 guidelines and for sperm DNA fragmentation index (sDFI). A total of 102 patients (57 PsA and 45 AxSpA) and 32 HC were included. The semen morphology, concentration, total motile count (TMC) and sDFI were comparable between patients and HC, while vitality was slightly lower in the patients' samples (81.2±7.6 vs. 84.4±4.5 for HC, p=0.02), although still within WHO normal range (>58%). Disease activity states did not affect semen parameters. Concentration and TMC values were lower in patients receiving conventional or biologic DMARDs monotherapy compared to untreated patients and those on combination therapy (p<0.05), but within normal ranges, and all other parameters were normal. Semen quality in men with PsA and AxSpA is comparable to that of HC. Neither disease activity nor anti-rheumatic drugs substantially affected sperm parameters. These findings are reassuring regarding potential effects on male reproductive health, although confirmation from longitudinal studies is warranted.

  • The potency of cell-based assays to predict response to TNF inhibitor therapy

    by Noa Rose, Ari Polachek, Daniel Levinson, Ori Elkayam, Smadar Gertel

    Tumor necrosis factor inhibitors (TNFi) have revolutionized rheumatic and inflammatory diseases therapy. Despite their efficacy, at least 30% of patients do not respond to TNFi therapy. There are five FDA-approved TNFis and several TNFi biosimilars, which are equivalent to their reference drugs. Although all TNFi drugs neutralize the TNF cytokine, they differ in many structural and pharmacokinetic properties. These differences may lead to varying patient responses, making one TNFi, but not another, effective for a given patient. An accurate prediction of a priori responsiveness to therapy, rather than trial and error, would therefore be of great value. Biomarkers that may guide the optimal TNFi choice are an unmet need. The authors discuss the diagnostic and predictive utilities ofCell-Based Assays (CBAs) for individualized TNFi therapy selection based upon a given patient's immune cell response to the various TNFi drugs to predict the clinical outcomes to those drugs. CBAs allow to assess response to multiple TNFi drugs simultaneously by measurement of biomarkers that could distinguish between TNFi responders and non-responders, effectively prioritizing the TNFi of choice. This literature search focuses upon biomarkers and techniques that could be used as predictive CBAs for clinical response to TNFi.

  • Open Access

    Therapeutic Potential of Adipose Mesenchymal Stem Cells for Synovial Regeneration: from In-Vitro Studies to Clinical Applications

    by Daniel Levinson, Almog Uziel, Victoria Furer, Ari Polachek, Ori Elkayam, Eyal Gur, Yoav Barnea, Inna Solodeev, Smadar Gertel

    Synovial joint disorders affect a substantial proportion of the global population, posing a significant challenge to the individual patient and global healthcare systems. Novel therapeutic strategies for resolving cartilage and synovial damage have recently been investigated. Adipose-derived mesenchymal stem cells (AD-MSCs) emerged as a potential cell-based therapy approach due to their accessibility, abundance, low immunogenicity, immunomodulatory effect, and tissue repair capability. The translation of AD-MSCs-based therapies from bench to clinical practice has shown promising results; with extensive evidence supporting their feasibility and efficacy for treating joint disorders. Despite their considerable potential, however, few AD-MSCs-based therapies have been approved for clinical application, primarily due to a lack of standardization and a poorly understood mechanism of action in vivo. The characterization of AD-MSCs from in vitro to in vivo models and eventually to clinical trials enables a comprehensive assessment of their therapeutic potential in synovial regeneration, bridging the gap between basic research and clinical application. The advantages and limitations collected from studies that delineate the effect of AD-MSCs on synovial cells will help researchers translate this cell-therapy approach from bench to clinical application. This review examines current models and applications of their therapeutic potential for synovial regeneration from in vitro studies to clinical trials. We also discuss the potential of cell-free therapy for joint disorders by means of extracellular vesicles. Graphical Abstract


  • Association of clinical and sonographic factors with discrepancy between patients’ and evaluators’ global assessments in psoriatic arthritis

    by Katya Meridor, Victoria Furer, Tzipora Shochat, Ofir Elalouf, Ori Elkayam, Ari Polachek

    Objectives: To evaluate the discordance between patients’ global assessments (PGA) and evaluators’ global assessments (EGA) in psoriatic arthritis (PsA), and to explore the association of clinical variables, patient-reported outcomes (PROs) and ultrasound (US) factors with this discordance. Methods: Consecutive PsA patients (CASPAR criteria) were prospectively recruited and evaluated by a comprehensive clinical examination, PROs and sonographic assessment (including 52 joints, 40 tendons and 14 entheses). EGA was scored by rheumatologists blinded to the PGA. Discordance between PGA and EGA was considered significant if the delta was ≥3. The US assessor was blinded to the clinical data. The concordant and discordant groups were compared, and factors associated with discordance were evaluated through a multivariate regression analysis. Results: Of the 158 PsA patients who were included, 88 (55.7%) patients were considered discordant, with the mean difference between PGA and EGA of 3.3. The discordant group had significantly higher tender joint counts (TJC), enthesitis, C-reactive protein (CRP) and lower working status rates compared with the concordant group (P < 0.05). US scores were similar between the groups. Patients with discordance had significantly higher PsA activity scores, a higher prevalence of fibromyalgia and worse PROs, including pain, depression, fatigue and measures of quality of life (P < 0.05). On multivariate regression, higher TJC, lower swollen joint counts and depression were associated with greater discordance (OR 1.07, OR 0.85 and OR 1.05, respectively, P < 0.05). Conclusion: The discrepancy between PGA and EGA in PsA is characterized by worse disease activity scores and worse subjective measures but not by sonographic measures.


  • A novel inhibitory pathway of synovial inflammation exerted by glucocorticoids and tumour necrosis factor inhibitors via lymphocyte activation gene-3 up-regulation: an ex vivo study

    by Smadar Gertel, Ari Polachek, Tali Eviatar, Ori Elkayam, Victoria Furer

    To investigate the impact of glucocorticoids (GCs) and anti-rheumatic drugs on the lymphocyte activation gene-3 (LAG-3) and on programmed cell death-1 (PD-1) expression on synovial and peripheral cells ex-vivo. Synovial fluid mononuclear cells (SFMCs) from psoriatic arthritis (PsA, n = 26) and rheumatoid arthritis (RA, n = 13) patients, SFCs from osteoarthritis (OA, n = 5) patients and peripheral blood mononuclear cells (PBMCs) of healthy donors (n = 14) were co-cultured with GCs, glucocorticoid receptor antagonist RU486, methotrexate (MTX) and biologics. LAG-3 and PD-1 expressions on immune subsets were analyzed by flow cytometry. GCs in PsA inhibited SFMCs growth vs medium (2.3 ± 0.4X105 vs 5.3 ± 0.7X105, respectively, p < 0.01) and markedly upregulated CD14+LAG-3+ cells (11.7 ± 2.4% vs 0.8 ± 0.3%, p < 0.0001, respectively), but not CD3+LAG-3+ and CD14+PD-1+ cells. MTX had no effect on CD14+LAG-3+ cells (0.7 ± 0.3%). The TNFi inhibitors, infliximab (IFX) and etanercept, but not IL-12/23i, upregulated CD14+LAG-3+ cells vs medium (2.0 ± 0.6% and 1.6 ± 0.4% vs 0.5 ± 0.1%, p < 0.03, respectively). SFMCs growth inhibition in both PsA and RA correlated with CD14+LAG-3+ cell upregulation (r = 0.53, p = 0.03). RU486 inhibited GC-induced CD14+LAG-3+ cell up-regulation in a dose-dependent manner compared with GC alone (5µM 5.3 ± 1.2% and 50µM 1.3 ± 0.5% vs 7.0 ± 1.4%, p < 0.003), but had no significant effect on CD14+LAG-3+ cells co-cultured with IFX. GCs in healthy donors’ PBMCs upregulated the immune subsets CD3+LAG-3+, CD14+LAG-3+ and CD14+PD-1+ cells. This study proposes a novel regulatory mechanism of GCs and of TNFi mediated by LAG-3 upregulation in synovial monocytes and PBMCs. LAG-3 modulation may be a promising target for development of novel therapies for inflammatory arthritis.


  • Open Access

    Identification of autoantibodies against PsoP27 in synovial fluid derived from psoriatic arthritis and rheumatoid arthritis patients

    by Marina Slobodkin, Ari Polachek, Victoria Furer, Ori Elkayam, Smadar Gertel

    PsoP27 is an antigen expressed in psoriatic lesions. It plays an inflammatory role in psoriasis. This study objective was to characterize antibodies (Abs) against PsoP27 in patients with psoriatic arthritis (PsA) and rheumatoid arthritis (RA). Levels of Abs against native and citrullinated PsoP27 in PsA and RA patients' synovial fluid (SF) and sera were determined by ELISA. SF of osteoarthritis (OA) patients and sera of healthy donors were used as controls. Levels of Abs against PsoP27 were correlated with disease activity scores. Abs against native and citrullinated PsoP27 levels in SF of PsA (n = 48; 0.38 +/- 0.03 and 0.44 +/- 0.04, respectively) and RA (n = 22; 0.57 +/- 0.1 and 0.62 +/- 0.09, respectively) were significantly higher than in OA patients (n = 23; 0.14 +/- 0.01 and 0.15 +/- 0.01, respectively) (p < .0001). For both Abs, there were no significant differences between their level in PsA and RA patients. There was no difference in the level of Abs against citrullinated PsoP27 in SF of seronegative versus seropositive RA patients. Levels of Abs against both native and citrullinated PsoP27 in the SF and level of systemic C-reactive protein in PsA correlated positively, while in RA there were no significant correlations with disease activity scores. No differences in level of Abs against PsoP27 were found in the sera of all three study groups. Abs against native and citrullinated PsoP27 are present in PsA and RA SF but not in those of OA patients, suggesting a potential role of those Abs in inflammatory joint diseases.


  • Open Access

    Anti-inflammatory effects of infliximab and methotrexate on peripheral blood and synovial fluid mononuclear cells: ex vivo study

    by S Gertel, M Rokach, A Polachek, I Litinsky, M Anouk, O Elkayam, V Furer

    Objective: To investigate the effects of methotrexate (MTX) and the tumour necrosis factor inhibitor infliximab (IFX) on immune cells derived from peripheral blood mononuclear cells (PBMCs) and synovial fluid mononuclear cells (SFMCs) of inflammatory arthritis patients. Method: Phytohaemagglutinin (PHA)-induced proliferation of healthy donors' PBMCs and synovial intermediate monocytes (CD14+CD16+ cells) in SFMCs derived from psoriatic arthritis (PsA) and rheumatoid arthritis (RA) patients was determined by flow cytometry following co-culture with IFX and MTX. PHA-induced interferon-gamma (IFN-gamma) production in PBMCs was measured by enzyme-linked immunosorbent assay. The drugs' effect on mRNA expression in SFMCs was determined by quantitative polymerase chain reaction. Results:The combination of IFX 10 mu g/mL + MTX 0.1 mu g/mL had the strongest inhibitory effect on PBMC proliferation (91%), followed by MTX 0.1 mu g/mL (86%) and IFX 10 mu g/mL (49%). In PHA-stimulated PBMCs, IFN-gamma production was reduced by IFX 10 mu g/mL, MTX 0.1 mu g/mL, and IFX 10 mu g/mL + MTX 0.1 mu g/mL by 68%, 90%, and 85%, respectively. In SFMCs, IFX 10 mu g/mL significantly reduced CD14+CD16+ cells compared to medium (PsA 54%, p < 0.01; RA 46%, p < 0.05), while MTX had no effect on this population. IFX + MTX led to a similar suppression of CD14+CD16+ cells as achieved by IFX alone. The drugs had different impacts on SFMC gene expression. Conclusion: Both IFX and MTX effectively inhibited PBMC proliferation and IFN-gamma production, but only IFX reduced synovial monocytes and pro-inflammatory gene expression in SFMCs, suggesting a differential impact of IFX and MTX on critical inflammatory cell populations ex vivo.


  • Open Access

    Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis: Overview of Therapies and a Personalized Approach to Optimized Combined Therapy

    by Noa Rose, Victoria Furer, Ari Polachek, Ori Elkayam, Smadar Gertel

    Immune checkpoint inhibitors (ICIs), including anti-cytotoxic T lymphocyte antigen 4, anti-programmed cell death 1, and anti-programmed cell death ligand 1 (PD-L1) antibodies, are currently widely used in oncology clinical practice, achieving considerable success in improving disease outcomes. New checkpoint targets are being discovered and investigated through basic science research and clinical trials. ICI remove negative regulatory immune signals on T cells, leading to immune activation and induction of antitumor immunity. Patients who receive ICI, however, are at risk for developing immune-related adverse events (irAEs), which are attributed to increased T cell activity against antigens in both tumors and in healthy tissues, to increased inflammatory cytokine levels, to increased levels of preexisting autoantibodies, and to enhanced complement-mediated inflammation. Arthritis is one of the most common irAEs. ICI-induced rheumatic irAEs are categorized by levels of severity which guide the choice of treatment options. Management of ICI-induced rheumatic irAEs includes the use of glucocorticoids, disease-modifying antirheumatic drugs (mainly methotrexate), and biological agents (e.g., tumor necrosis factor, interleukin-6 receptor, and CD20 inhibitors). This review aims to summarize the current ICI subtypes, their role in rheumatic irAEs development, and therapies current used in clinical practice to manage irAEs. In addition, we propose to use an ex vivo personalized diagnostic assay for the selection of the most effective ICI with antirheumatic drugs combinations that will inhibit the advancement of ICI-induced adverse events. Cite this article as: Rose N, Furer V, Polachek A, Elkayam O, Gertel S. Immune checkpoint inhibitor-induced inflammatory arthritis: Overview of therapies and a personalized approach to optimized combined therapy. Eur J Rheumatol. 2024;11(1):27-32.


  • Open Access

    Circulating and Synovial Monocytes in Arthritis and Ex-Vivo Model to Evaluate Therapeutic Modulation of Synovial Monocytes

    by Adam Slavick, Victoria Furer, Ari Polachek, Reut Tzemach, Ori Elkayam, Smadar Gertel

    Monocytes are innate immune cells that play a dual role in protection of host against pathogens and initiation and perpetuation of inflammatory disorders including joint diseases. During inflammation, monocytes migrate from peripheral blood to tissues via chemokine receptors where they produce inflammatory factors. Monocytes are classified into three subsets, namely: classical, intermediate and non-classical, each subset has particular function. Synovium of patients with inflammatory joint diseases, such as rheumatoid arthritis and psoriatic arthritis as well as osteoarthritis, is enriched by monocytes that differ from circulatory ones by distinct subsets distribution. Several therapeutic agents used systemically or locally through intra-articular injections in arthritis management modulate monocyte subsets. This scoping review summarized the existing literature delineating the effect of common therapeutic agents used in arthritis management on circulating and synovial monocytes/macrophages. As certain agents have an inhibitory effect on monocytes, we propose to test their potential to inhibit synovial monocytes via an ex-vivo platform based on cultured synovial fluid mononuclear cells derived from patients with rheumatic diseases. Information obtained from the ex-vivo platform can be applied to explore the therapeutic potential of medications in clinical practice.